Cited 0 times in
S78: Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.